Back
26
Also listed as
CZMWY
OTC
Day Range
$29.16
$33.46
52-Week Range
$26.42
$70.88
Volume
300
50D / 200D Avg
$34.31
/
$49.41
Prev Close
$29.16
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 18.1 | 0.4 |
| P/B | 1.2 | 2.9 |
| ROE % | 6.8 | 3.8 |
| Net Margin % | 6.3 | 3.9 |
| Rev Growth 5Y % | 7.9 | 10.0 |
| D/E | 0.1 | 0.2 |
Key Takeaways
Revenue grew 7.85% annually over 5 years — modest growth
Earnings declined -20.99% over the past year
Debt/Equity of 0.06 — conservative balance sheet
Generating 200.03M in free cash flow
Cash machine — converts 141.65% of earnings into free cash flow
Capital efficient — spends only 2.08% of revenue on capex
Growth
Revenue Growth (5Y)
7.85%
Revenue (1Y)7.82%
Earnings (1Y)-20.99%
FCF Growth (3Y)20.83%
Quality
Return on Equity
6.79%
ROIC7.45%
Net Margin6.34%
Op. Margin10.02%
Safety
Debt / Equity
0.06
Current Ratio2.34
Interest Coverage8.39
Valuation
P/E Ratio
18.08
P/B Ratio1.21
EV/EBITDA11.90
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7.82% | Revenue Growth (3Y) | 3.26% |
| Earnings Growth (1Y) | -20.99% | Earnings Growth (3Y) | -30.27% |
| Revenue Growth (5Y) | 7.85% | Earnings Growth (5Y) | -12.08% |
| Profitability | |||
| Revenue (TTM) | 2.23B | Net Income (TTM) | 141.21M |
| ROE | 6.79% | ROA | 4.15% |
| Gross Margin | 52.76% | Operating Margin | 10.02% |
| Net Margin | 6.34% | Free Cash Flow (TTM) | 200.03M |
| ROIC | 7.45% | FCF Growth (3Y) | 20.83% |
| Safety | |||
| Debt / Equity | 0.06 | Current Ratio | 2.34 |
| Interest Coverage | 8.39 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 18.08 | P/B Ratio | 1.21 |
| P/S Ratio | 1.15 | PEG Ratio | -1.32 |
| EV/EBITDA | 11.90 | Dividend Yield | 0.02% |
| Market Cap | 2.55B | Enterprise Value | 2.66B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.23B | 2.07B | 2.09B | 1.90B | 1.65B |
| Net Income | 141.21M | 178.73M | 290.40M | 293.91M | 236.28M |
| EPS (Diluted) | 1.61 | 2.01 | 3.25 | 3.29 | 2.64 |
| Gross Profit | 1.18B | 1.09B | 1.21B | 1.13B | 967.21M |
| Operating Income | 223.32M | 121.35M | 327.14M | 396.88M | 350.91M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 3.40B | 3.39B | 3.03B | 2.82B | 2.40B |
| Total Liabilities | 1.28B | 1.34B | 860.02M | 792.73M | 718.59M |
| Shareholders' Equity | 2.12B | 2.04B | 2.16B | 2.02B | 1.66B |
| Total Debt | 132.46M | 151.35M | 155.70M | 127.90M | 121.27M |
| Cash & Equivalents | 27.27M | 20.29M | 10.60M | 7.73M | 7.44M |
| Current Assets | 1.27B | 1.21B | 1.91B | 1.79B | 1.60B |
| Current Liabilities | 543.81M | 568.84M | 561.65M | 539.32M | 448.12M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#884 of 1023
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026